Trials / Completed
CompletedNCT03158103
A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
A Phase I Study of Binimetinib in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety and tolerability of the combination of pexidartinib and MEK162. This study tests different doses of pexidartinib in combination with different doses of MEK162 to see which dose combination of these drugs is safe and best tolerated in people.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEK162 | MEK162 at 30mg twice daily |
| DRUG | Pexidartinib | pexidartinib 600mg daily (400mg in the morning, 200mg at night) for 4 weeks (1 cycle) |
Timeline
- Start date
- 2017-04-15
- Primary completion
- 2021-04-28
- Completion
- 2021-04-28
- First posted
- 2017-05-17
- Last updated
- 2021-04-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03158103. Inclusion in this directory is not an endorsement.